Long COVID Patterns in the RECOVER-Adult Study
November 21, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Agrylin
Synonyms :
anagrelide
Class :
PDE-3 Inhibitors, Phospholipase A2 Inhibitors, Hematologic, Antiplatelet Agents
Brand Name :
Agrylin
Synonyms :
anagrelide
Class :
PDE-3 Inhibitors, Phospholipase A2 Inhibitors, Hematologic, Antiplatelet Agents
Dosage Forms & Strengths  Â
CapsuleÂ
0.5 mgÂ
1 mgÂ
0.5 mg orally every 6 hour or 1 mg every 12 hour
enhance the dose as needed maximum up to 0.5 mg/day/week Not more than 2.5 mg/dose or 10 mg/day
Platelet count responds generally within 7 to 14 days; required completion time for action is 4 to 12 weeks
Dosage Forms & Strengths  Â
CapsuleÂ
0.5 mgÂ
1 mgÂ
Refer to adult dosingÂ
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
when both drugs are combined, there may be increased toxicity of anagrelide by QTC interval  
may increase the anticoagulant effect of antiplatelet agents
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
may have an increased anticoagulant effect when combined with heparin
anagrelide and loperamide are both known to elevate the QTc interval
It may enhance QTc interval when combined with lithium
anagrelide: it may increase the risk of QTc prolongation agents
anagrelide: it may increase the risk of QTc prolongation agents
anagrelide: it may increase the risk of QTc prolongation agents
anagrelide: it may increase the risk of QTc prolongation agents
anagrelide: it may increase the risk of QTc prolongation agents
when both drugs are combined, there may be an increased risk or severity of QTC prolongation  
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be increase in both increase QTc interval 
when both drugs are combined, there may be increase in both increase QTc interval 
antiplatelet Properties may enhance the antiplatelet effect of abrocitinib
may enhance the effects of the other by pharmacodynamic synergism
antiplatelet agents increase the antiplatelet effect of abrocitinib
It may enhance QTc interval when combined with pentamidine
The efficacy of anagrelide may be increased by aspirin rectal due to pharmacodynamic synergism
it may enhance the anticoagulant effect of anticoagulants
it may enhance the anticoagulant effect of anticoagulants
it may enhance the anticoagulant effect of anticoagulants
it may enhance the anticoagulant effect of anticoagulants
it may enhance the anticoagulant effect of anticoagulants
it May enhance the antiplatelet effect of Agents with antiplatelet Properties
it May enhance the antiplatelet effect of Agents with antiplatelet Properties
it May enhance the antiplatelet effect of Agents with antiplatelet Properties
it May enhance the antiplatelet effect of Agents with antiplatelet Properties
it May enhance the antiplatelet effect of Agents with antiplatelet Properties
antiplatelet agents may enhance the anticoagulant effect of thrombolytic Agents
choline magnesium trisalicylate
may enhance the adverse/toxic effect of salicylates
may increase the anticoagulant effect of anticoagulants
may increase the anticoagulant effect of anticoagulants
may increase the anticoagulant effect of anticoagulants
may increase the anticoagulant effect of anticoagulants
may increase the anticoagulant effect of anticoagulants
choline magnesium trisalicylate
may increase the risk of adverse effect of salicylates
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may enhance the risk of adverse effect of thrombolytic agents
It may enhance the risk of bleeding by affecting coagulation when combined with omega-3 carboxylic acids
It may enhance effects when combined with inamrinone by pharmacodynamic synergism
anagrelide: they may enhance serum concentrations of CYP1A2 Inhibitors
anagrelide: they may enhance serum concentrations of CYP1A2 Inhibitors
anagrelide: they may enhance serum concentrations of CYP1A2 Inhibitors
anagrelide: they may enhance serum concentrations of CYP1A2 Inhibitors
anagrelide: they may enhance serum concentrations of CYP1A2 Inhibitors
anagrelide: they may increase the antiplatelet effect of antiplatelet agents
anagrelide: they may increase the antiplatelet effect of antiplatelet agents
anagrelide: they may increase the antiplatelet effect of antiplatelet agents
anagrelide: they may increase the antiplatelet effect of antiplatelet agents
anagrelide: they may increase the antiplatelet effect of antiplatelet agents
The potential for bleeding to occur at a higher risk or increased severity when antipyrine is used in conjunction with anagrelide
anagrelide: they may increase the antiplatelet effect of antiplatelet properties
anagrelide: they may increase the antiplatelet effect of antiplatelet properties
anagrelide: they may increase the antiplatelet effect of antiparasitic agents
anagrelide: they may increase the antiplatelet effect of antiparasitic agents
anagrelide: they may increase the antiplatelet effect of antiparasitic agents
anagrelide: they may increase the antiplatelet effect of antiparasitic agents
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
Combining tegafur with anagrelide can reduce tegafur’s metabolism
When anagrelide is used together with sertraline, the risk or seriousness of bleeding may be enhanced
The potential for bleeding risk or its seriousness may elevate when anagrelide is used together with troxerutin
When anagrelide is used together with capsaicin, this leads to enhanced risk or seriousness of methemoglobinemia
When anagrelide is used together with somatotropin, this leads to a rise in aminophylline’s metabolism
When ponesimod is used together with anagrelide, this leads to enhanced risk or seriousness of bradycardia
When anagrelide is used together with adenosine, this leads to enhanced risk or seriousness of QTc prolongation
When anagrelide is used together with givinostat, this leads to enhanced risk or severity of Qtc prolongation
anagrelide: they may enhance the serum concentration of CYP2D6 Inhibitors
anagrelide: they may enhance the serum concentration of CYP2D6 Inhibitors
anagrelide: they may enhance the serum concentration of CYP2D6 Inhibitors
anagrelide: they may enhance the serum concentration of CYP2D6 Inhibitors
anagrelide: they may enhance the serum concentration of CYP2D6 Inhibitors
anagrelide: it may increase the risk or severity of CNS depression
anagrelide: it may increase the risk or severity of CNS depression
anagrelide: it may increase the risk or severity of CNS depression
anagrelide: it may increase the risk or severity of CNS depression
anagrelide: it may increase the risk or severity of CNS depression
anagrelide: it may decrease the metabolism of oxtriphylline
anagrelide: it may decreased the serum concentration of CNS depressants
anagrelide: it may decreased the serum concentration of CNS depressants
anagrelide: it may decreased the serum concentration of CNS depressants
combining anagrelide with dapoxetine may increase the intensity of hemorrhage
the chances of bleeding can be heightened when morniflumate is administered in conjunction with anagrelide
anagrelide: it may decrease activities of antihypertensive drugs
anagrelide: it may decrease activities of antihypertensive drugs
anagrelide: it may decrease activities of antihypertensive drugs
anagrelide: it may decrease activities of antihypertensive drugs
anagrelide: it may decrease activities of antihypertensive drugs
anagrelide: it may increase the risk of bleeding with trapidil
the risk or extent of tachycardia can be raised when anagrelide is combined with clidinium
the risk or extent of tachycardia can be raised when anagrelide is combined with isometheptene
anagrelide: it may decrease the metabolism of rosoxacin
QTc intervals are increased both by lenvatinib and anagrelide.
when both drugs are combined, there may be an increased QTC interval  
CYP1A2 inhibitors increase the concentration of anagrelide in serum
it may increase the antiplatelet effect of properties of antiplatelet drugs
antiplatelet agents may enhance the adverse/toxic effect of ibritumomab tiuxetan
l-methylfolate-pyridoxal 5′-phosphate-methylcobalamine
it may enhance the antiplatelet effect of Agents with antiplatelet Properties
l-methylfolate-pyridoxal 5′-phosphate-methylcobalamine
may increase the antiplatelet effect of agents with antiplatelet properties
may increase the antiplatelet effect of agents with antiplatelet properties
may increase the antiplatelet effect of agents with antiplatelet properties
may increase the antiplatelet effect of agents with antiplatelet properties
may increase the antiplatelet effect of agents with antiplatelet properties
may increase the antiplatelet effect of agents with antiplatelet properties
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may increase the antiplatelet effect of prostacyclin analogs
may enhance the effect of antiplatelet properties
may increase the anti-coagulant action of anti-coagulants
may increase the risk or severity of gastrointestinal bleeding when combined
May have an increased antiplatelet effect when combined with Antiplatelet agents
may have an increasingly adverse effect when combined with Apixaban
May have an increased anticoagulant effect when combined with Antiplatelet agents
may have an increasingly adverse effect when combined with Edoxaban
may increase the toxic effect of salicylates
may have an increased antiplatelet effect when combined with antiplatelet agents
may have an increased antiplatelet effect when combined with antiplatelet agents
may have an increased antiplatelet effect when combined with antiplatelet agents
other antiplatelet agents increase the toxicity of cephalothin
it increases the effect of antiplatelet agents
may increase the adverse effect of pentosan polysulfate sodium
may increase the antiplatelet effect
may have an increasingly adverse effect when combined with obinutuzumab
antiplatelet agents increase the effect of anticoagulants
antiplatelet agents increase the effect of anticoagulants
antiplatelet agents increase the effect of anticoagulants
antiplatelet agents increase the effect of anticoagulants
antiplatelet agents increase the effect of anticoagulants
it increases the toxicity of antiplatelet agents
it increases the effect of antiplatelet agents
it increases the effect of antiplatelet agents
it increases the efficacy of antiplatelet agents
other antiplatelet agents increase the toxicity of ibritumomab tiuxetan
pirtobrutinib: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K: they may increase the antiplatelet effect of antiplatelet agents
Vitamin K: they may increase the antiplatelet effect of antiplatelet agents
Vitamin D analogs: they may increase the antiplatelet effect of antiplatelet agents
anagrelide: they may increase the antiplatelet effect of antiplatelet properties
Bile Acid Sequestrants: they may diminish the absorption of Antiplatelet Agent
inotersen: they may increase the antiplatelet effect of antiplatelet agents
verteporfin: they may increase the antiplatelet effect of Agents with antiplatelet agentss
selumetinib: they may increase the antiplatelet effect of Agents with antiplatelet properties
zuclopenthixol: they may increase the antiplatelet effect of Agents with antiplatelet properties
etravirine: they may increase the antiplatelet effect of Agents with antiplatelet agent
combining zimelidine with anagrelide may increase the chances of hemorrhage
the risk of tachycardia may be increased
the risk of bleeding may be increased
the risk of bleeding may be increased
Actions and Spectrum:Â
anagrelide’s exact method of action is unknown, although it is thought to function by blocking the activity of the enzyme cyclic AMP phosphodiesterase III (PDE III), which breaks down cyclic AMP. This causes a rise in intracellular cyclic AMP, which in turn causes platelet and megakaryocyte production to fall.Â
anagrelide is a selective inhibitor of megakaryocyte maturation and platelet formation in terms of its spectrum. Both coagulation factors and other blood cells are not significantly impacted.Â
Frequency defined Â
1-10%Â
Rash (8%)Â
Chest pain (8%)Â
Pharyngitis (7%)Â
Malaise (6%)Â
Cough (6%)Â
Paresthesia (6%)Â
ArthralgiaÂ
Flatulence (10%)Â
Heart failureÂ
HemorrhageÂ
HypertensionÂ
Anorexia (8%)Â
Pruritus (6%)Â
Confusion (1-5%)Â
Vomiting (10%)Â
MyalgiaÂ
NervousnessÂ
PhotosensitivityÂ
Fever (9%)Â
Edema (9%)Â
Flu symptomsÂ
Leg crampsÂ
DehydrationÂ
DyspepsiaÂ
AnemiaÂ
Elevated liver enzymesÂ
Tachycardia (8%)Â
GastritisÂ
Back pain (6%)Â
VasodilationÂ
BronchitisÂ
RhinitisÂ
Vision abnormalitiesÂ
AnginaÂ
Postural hypotensionÂ
SyncopeÂ
ThrombosisÂ
ArrhythmiaÂ
Cardiovascular diseaseÂ
DepressionÂ
SinusitisÂ
ConstipationÂ
>10%Â
Headache (44%)Â
General pain (15%)Â
Dyspnea (12%)Â
Asthenia (23%)Â
Nausea (17%)Â
Abdominal pain (16%)Â
Dizziness (15%)Â
Edema (21%)Â
Palpitations (26%)Â
Diarrhea (26%)Â
Post marketing reportsÂ
Tubulointerstitial nephritisÂ
Supraventricular tachycardiaÂ
Cerebral infarctionÂ
Cardiovascular toxicityÂ
Pulmonary hypertensionÂ
Interstitial lung diseases, including allergic alveolitis Â
Bleeding riskÂ
Pulmonary toxicityÂ
Torsades de pointesÂ
Eosinophilic pneumonia and interstitial pneumonitisÂ
HepatotoxicityÂ
HypoesthesiaÂ
Black Box WarningÂ
The medicine may raise the chance of developing congestive heart failure (CHF), which is a disease in which the heart is unable to pump blood efficiently, according to the black box warning for anagrelide. Â
Additionally, anagrelide may raise the risk of myocardial infarction (heart attack) and arrhythmias (abnormal heart rhythms).Â
Contraindication/Caution:Â
Contraindication:Â
Caution:Â
Pregnancy warnings:    Â
Pregnancy category: N/AÂ
Lactation: Excretion into human milk is unknownÂ
Pregnancy Categories:        Â
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.Â
Category B: There were lack of studies on pregnant women and no evidence of risk to the foetus in animal experiments.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category
PharmacologyÂ
An agent that lowers platelets, anagrelide is a member of the group of drugs known as phosphodiesterase III (PDE III) inhibitors. It functions by preventing megakaryocytes, the cells that make platelets, from maturing. As a result, there are less platelets in the blood, which effectively treats essential thrombocythemia, a condition in which platelets are produced in excess.Â
PharmacodynamicsÂ
anagrelide’s mode of action, which includes the reduction of platelet formation, is connected to its pharmacodynamics. A decrease in platelet formation in the bone marrow is caused by anagrelide’s specific inhibition of megakaryocyte maturation.Â
PharmacokineticsÂ
Absorption  Â
After oral treatment, anagrelide is quickly absorbed, and peak plasma concentrations are attained in 1 to 2 hours. anagrelide has a bioavailability of about 75% and is not greatly impacted by dietary consumption.Â
DistributionÂ
anagrelide has a large volume of distribution, which suggests that it disperses widely into bodily tissues. Most of the drug’s protein binding (97%) occurs to alpha-1 acid glycoprotein.Â
MetabolismÂ
anagrelide undergoes substantial hydrolysis, oxidation, and glucuronidation in the liver. The main metabolite, 3-hydroxyanagrelide, contains around 40% of the activity of anagrelide and is pharmacologically active. The cytochrome P450 (CYP) enzyme system metabolises anagrelide predominantly, with CYP1A2 and CYP3A4 being the key enzymes involved.Â
Elimination and excretionÂ
Less than 1% of anagrelide is excreted in the feces and is predominantly eliminated in the urine. anagrelide has an elimination half-life of about 1-2 hours, whereas the active metabolite, 3-hydroxyanagrelide, has an elimination half-life of around 4 hours. About 65% of the dosage of anagrelide is excreted unaltered in the urine, with renal excretion being the main route of clearance.Â
Administration: Â
anagrelide is a medication that may be taken orally in the form of capsules. anagrelide should be taken at the same times every day to maintain constant blood levels. The common beginning dose for anagrelide is typically 0.5 mg orally four times a day.Â
Patient information leafletÂ
Generic Name: anagrelideÂ
Why do we use anagrelide?Â
anagrelide is mostly used to treat essential thrombocythemia (ET), a myeloproliferative condition characterised by excessive platelet production. Â
anagrelide is used to lower the blood’s platelet count, which can aid in reducing the risk of bleeding, blood clots, and other problems related to ET.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
